A.   Provide another prescribed medication.

B.   Administer four doses at 15-second intervals.

C.   Administer a second dose.

D.   Continue to monitor consciousness for 2 minutes.

A.   Ramelteon

B.   Eszopiclone

C.   Zolpidem

D.   Zaleplon

A.   Sleepwalking

B.   Deep sleep

C.   Relaxation

D.   Dozing

A.   Daytime fatigue

B.   Vivid dreams

C.   Bedwetting

D.   Sleepwalking

A.   Short-acting barbiturates

B.   Ultra-short-acting barbiturates

C.   Intermediate-acting barbiturates

D.   Long-acting barbiturates

A.   Drug allergy

B.   Cardiac disease

C.   Epileptic disease

D.   Narrow-angle glaucoma

A.   Prevention of lightheadedness

B.   Relief of nerve pain

C.   Reduction of muscle rigidity

D.   Reduction of choreiform movement

A.   Increased perspiration

B.   Increased body weight

C.   Bedwetting

D.   Sleepwalking

A.   Alprazolam

B.   Ramelteon

C.   Midazolam

D.   Eszopiclone

A.   Diazepam

B.   Dantrolene

C.   Cyclobenzaprine

D.   Baclofen

A.   Decreased heart rate

B.   Amnesia

C.   Constipation

D.   Dry mouth

A.   Verapamil

B.   Flumazenil

C.   Olanzapine

D.   Rifampin

A.   The drug acts on benzodiazepine receptors that play a role in alcohol addiction.

B.   The drug may reduce the memory of painful symptoms related to alcohol withdrawal.

C.   The patient may need to be sedated to relieve symptoms of alcohol withdrawal.

D.   The drug acts on gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS).

A.   Oxytocin

B.   Phenobarbital

C.   Ceftriaxone

D.   Sulfamethoxazole

A.   Phenobarbital

B.   Pentobarbital

C.   Butabarbital

D.   Mephobarbital

A.   Prolonged benzodiazepine action

B.   Increased central nervous system (CNS) depression

C.   Decreased benzodiazepine effects

D.   Increased daytime sleepiness

A.   Activated charcoal

B.   Flumazenil

C.   Olanzapine

D.   Furosemide

A.   Presence of benzodiazepine receptors adjacent to the receptors responsible for alcohol addiction

B.   Suppression of gamma-aminobutyric acid (GABA) receptors

C.   Inhibition of nerve impulse transmission

D.   Amnesic properties

A.   Encouraging the patient to maintain a well-balanced diet

B.   Instructing the patient to take low doses of benzodiazepines

C.   Recommending that the patient consume a glass of warm lactose-free milk at bedtime

D.   Teaching the patient about meditation

A.   Phenylephrine at a maximum dose of 2 mg

B.   Phenylephrine at a maximum dose of 5 mg

C.   Flumazenil at a maximum dose of 3 mg

D.   Flumazenil at a maximum dose of 1 mg

A.   The patient is experiencing a barbiturate overdose.

B.   The patient is experiencing benzodiazepine toxicity.

C.   The patient was administered azole along with benzodiazepine.

D.   The patient is experiencing a muscle-relaxant overdose.

A.   Pentobarbital

B.   Zaleplon

C.   Diazepam

D.   Ramelteon

A.   Sleeping more during the day

B.   Establishing a set sleep pattern

C.   Avoiding tobacco at bedtime

D.   Avoiding alcohol at bedtime

A.   Flurazepam

B.   Midazolam

C.   Temazepam

D.   Diazepam

A.   Dyspnea

B.   Hallucinations

C.   Alertness

D.   Ataxia

A.   Ipecac syrup

B.   Activated charcoal

C.   Naloxone

D.   Flumazenil

A.   Degree of patient responsiveness to the drug given

B.   Degree of inhibition of nerve impulse transmission to the CNS

C.   Dose of the drug used to produce the effect on the CNS

D.   Duration of action on the central nervous system (CNS)

A.   Temazepam induces sleep in approximately 1 hour.

B.   The therapeutic activity of temazepam is reduced with sleep.

C.   Temazepam causes early awakening after sleep.

D.   Temazepam may cause gastrointestinal upset.

A.   Infusion of other drugs

B.   Intravenous infiltration

C.   Infusion without dilution

D.   Infusion that is too rapid

A.   Take lower doses of benzodiazepines.

B.   Use home remedies of vegetables and herbs.

C.   Go to acupuncture therapy.

D.   Drink lactose-free milk at bedtime.

A.   Zolpidem, Diazepam, Midazolam

B.   Diazepam, Midazolam, Eszopiclone

C.   Diazepam, Ramelteon, Midazolam

D.   Zolpidem, Ramelteon, Eszopiclone

A.   Maintenance of an adequate airway

B.   Administration of activated charcoal

C.   Administration of intravenous fluids

D.   Administration of furosemide

A.   "I will stop drinking coffee at least 6 hours before bedtime."

B.   "I should avoid exercise just before going to bed."

C.   "I may be prescribed benzodiazepines to promote sleep."

D.   "I will have a glass of warm milk before bed."

A.   Request a prescription to increase the dosage of pentobarbital.

B.   Instruct the patient to increase the dosage of the contraceptive drug.

C.   Suggest an alternate contraceptive method to the patient.

D.   Recommend discussing an alternative drug for seizures with the primary health care provider.

A.   Delirium tremens

B.   Tonic-clonic seizure

C.   Malignant hyperthermia

D.   Respiratory arrest

A.   Avoid using this drug to induce sleep.

B.   Take the drug 30 minutes before sleeping.

C.   Drink coffee or tea in the morning.

D.   Use the lowest effective dosage.

A.   Produces drowsiness, lethargy, and blurred vision

B.   Causes gastrointestinal distress

C.   Increases pain associated with activities

D.   Impairs coordinated movements

A.   Butabarbital

B.   Thiopental

C.   Pentobarbital

D.   Phenobarbital

A.   Hypotension, Drug allergy, Status epilepticus

B.   Hypotension, Status epilepticus, Pregnancy

C.   Pregnancy, Drug allergy, Significant respiratory difficulties

D.   Significant respiratory difficulties, Hypotension, Status epilepticus

A.   "Take the medication with food or milk."

B.   "Allow at least 8 hours for sleep."

C.   "Expect and prepare for a daytime hangover."

D.   "Report palpitations to the primary health care provider."

A.   Drinks grapefruit juice along with diazepam

B.   Takes rifampin along with diazepam

C.   Takes phenobarbital along with diazepam

D.   Takes olanzapine along with diazepam

A.   Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI), Atypical antidepressants

B.   Monoamine oxidase inhibitor (MAOI), Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI)

C.   Selective serotonin reuptake inhibitor (SSRI), Tricyclic antidepressant, Serotonin-norepinephrine reuptake inhibitor (SNRI)

D.   Tricyclic antidepressant, Monoamine oxidase inhibitor (MAOI), Atypical antidepressants

A.   Liver dysfunction

B.   Kidney dysfunction

C.   Narrow-angle glaucoma

D.   Bronchial asthma

A.   Clonazepam

B.   Temazepam

C.   Alprazolam

D.   Eszopiclone

A.   Baclofen

B.   Diazepam

C.   Zaleplon

D.   Pentobarbital

A.   Assessing the patient’s risk for injury or falls

B.   Encouraging the patient to drink more fluids

C.   Monitoring for suicidal tendencies

D.   Monitoring the patient’s renal and hepatic function

A.   Airway maintenance

B.   Comfort measures

C.   Antidote preparation

D.   Seizure precautions

A.   Level of consciousness

B.   Indicators of infection

C.   Amount of bleeding

D.   Muscle spasms

A.   0.2 mg (2 mL) of flumazenil was given intravenously (IV).

B.   A high dose of flumazenil was given.

C.   The half-life of flumazenil is short.

D.   Alcohol was consumed with the benzodiazepines.

A.   Alprazolam

B.   Ramelteon

C.   Eszopiclone

D.   Zaleplon

A.   "Nowadays I sleep for long hours."

B.   "I feel like I breathe too deeply."

C.   "I sleep less than I used to."

D.   "I often feel dizzy and lightheaded."

A.   0.2 mg (2 mL) IV over 15 seconds

B.   0.5 mg (5 mL) IV over 30 seconds

C.   0.2 mg (2 mL) intravenously (IV) over 30 seconds

D.   0.2 mg (2 mL) IV over 60 seconds